Microstructure Imaging Gains FDA Clearance for MICSI-RMT

Microstructure Imaging, a YCombinator-backed NYU Langone Health spinout, has received FDA 510k clearance for its MICSI-RMT software suite, which is designed to enhance MRI image quality. This clearance marks the clinical translation of advanced MRI research led by Gregory Lemberskiy, CEO, and Benjamin Ades-aron, CTO.

 

MICSI-RMT is a significant breakthrough as the first market solution designed to enhance the signal-to-noise ratio (SNR) for diffusion and functional MRI. The software employs a random matrix theory-based algorithm to significantly improve MRI image quality through the redundancy of the MRI exam. 

 

Diffusion MRI involves the exponential signal suppression for contrast, often resulting in images with high noise levels. MICSI-RMT is the first solution to directly address the noise problem. Also, unlike traditional AI methods, MICSI-RMT achieves these remarkable results without the need for external training data or high-performance GPUs.

 

MICSI-RMT includes processing modules that support weighted linear least squares and Bayesian fitting techniques to facilitate quantitative analysis of diffusion-weighted imaging. The system also features DICOM data routing to secure a seamless integration into medical workflows.

 

In the study, the software demonstrated notable enhancements in the signal-to-noise ratio (SNR), with MICSI-RMT showing improvements of up to 4.35x for diffusion MRI (dMRI) and 1.9x for functional MRI (fMRI). MISCI-RMT also achieved dMRI enhancement and achieved a notable improvement in parameter precision. Specifically, the precision of ADC maps was improved by over 56.3%.

 

In a randomized, blinded rater study, expert neuroradiologists assessed MRI images processed by MICSI-RMT and standard of care (SOC). The MICSI-RMT processed images were preferred for their clarity and reduced artifacts, achieving higher expert image quality scores compared to standard diagnostic images. Raters found that DTI images processed with MICSI-RMT had improved visualization of small structures in brain white matter and improved contrast to distinguish adjacent tissue types, and for fMRI, more anatomically appropriate activation maps.

 

This advancement not only boosts diagnostic accuracy but also sets a new standard in neurology care, positioning MICSI-RMT as an essential tool for medical imaging professionals.